Insider trade

Officer sold ~$201K of KRYS shares in the open market

Traded Mar 2, 2026 · Filed Mar 3, 2026

Why it stands out

Krystal Biotech's Chief Accounting Officer sold $201K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$200,700

Shares × reported transaction price

Timing vs results

13 days after results of Feb 17, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−3.8%	−1.3%	−2.5%
30 days	−1.2%	−3.8%	+2.6%
90 days	+10.7%	+10.9%	−0.2%
180 days	+35.6%	+12.0%	+23.6%

Past results only. Not a forecast.

The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.

Scheduled in advanceFiled 7mo ago

Automatic saleFiled 7mo ago

Automatic saleFiled 7mo ago